INTRODUCTIONOxadiazole is a unique class of heterocycle, possessing numerous important biomedical and therapeutic applications, such as anti-bacterial, anti-cancer, anti-inflammatory, inhibitors for diverse enzymes, receptor modulators, and neuroprotective properties. The rapid development in the field of oxadiazole-containing structures is confirmed by the development of numerous clinical drugs, such as doxazosin, nesapidil, pleconaril, fasiplon, ataluren, zibotentan, and prenoxdiazine as selected examples.AREAS COVEREDThis review provides a comprehensive overview of the range of biological applications of oxadiazole-containing drugs in a range of patents from 2013 to 2021. The information was collected from available data sources including SciFinder, Reaxys, MedLine, and Chemical Abstracts.EXPERT OPINIONOxadiazole is an established class of compounds with fascinating biological properties. The importance of oxadiazoles can be recognized by their enormous application in a wide spectrum of medicinal chemistry from anticancer, lantibiotics, and antidiabetics to their use in agriculture and neuroprotection. For instance, the oxadiazole-based compounds have shown the ability to modulate a variety of receptors including the M4 receptor agonists, S1P1 receptor modulators, SSTR5 antagonists, orexin type-2 receptor agonists, liver X receptor agonists, and many more. This testifies to the special features associated with the oxadiazole scaffold, making it a significant pharmacophore.

01 Mar 2007·Congenital AnomaliesQ4 · MEDICINE

No teratogenic effect of prenoxdiazine: A population‐based case–control study

Q4 · MEDICINE

Article

Author: Andrew E. Czeizel ; Zoltan Bártfai ; Erzsébet H. Puhó ; Akos Somoskövi

ABSTRACT The objective of this study was to investigate the human teratogenic potential of oral prenoxdiazine treatment during pregnancy. The analysis of cases with congenital abnormalities and their matched controls without congenital abnormalities was performed in the large population‐based data set of the Hungarian Case–Control Surveillance of Congenital Abnormalities, 1980–1996. Of the 22 843 pregnant women who had offspring with congenital abnormalities, 158 (0.7%) were treated with prenoxdiazine. Of the 38 151 pregnant women who had babies without any defects in the study period (control group), 226 (0.6%) were treated with prenoxdiazine (adjusted prevalence odds ratio, 1.0; 95% confidence interval, 0.8–1.3). The comparison of cases and their matched controls did not show a significantly higher rate of prenoxdiazine treatment during the second and third months of gestation in the total (adjusted prevalence odds ratio, 1.4; 95% confidence interval, 0.9–2.2) or in any group of congenital abnormalities. Treatment with prenoxdiazine during pregnancy did not have any teratogenic risk to the fetus. Thus, prenoxdiazine treatment in pregnant women with an unproductive cough may be beneficial.

01 Jan 2004·Bratislavske lekarske listy

Antitussive effect of diltiazem in experimental conditions.

Article

Author: Franova, S ; Nosalova, G

BACKGROUNDCough is the most important defence reflex of the airways. Little information exists about participation of the ion channels in the mechanism of the cough reflex.OBJECTIVESThe aim of the study was to investigate the effect of diltiazem administration on the sensitivity of the mechanically induced cough reflex in experimental conditions.METHODSMechanical stimulation of the laryngopharyngeal and tracheobronchial area of the airways in non-anaesthetized cats was used in this experiment. The number of cough efforts, and the frequency and intensity of the cough attack were utilized as evaluated parameters.RESULTSPerorally administered diltiazem (30 mg/kg b.w.) caused a statistically significant decrease of measured cough parameters. Cough - suppressing activity of diltiazem was lower than codeine, but higher than dropropizine and prenoxdiazine.CONCLUSIONExperimental results showed antitussive activity of the calcium-channel blocker diltiazem and suggested the role of voltage-gated calcium channels of type L in mechanism of the cough reflex. (Fig. 4, Ref. 15.).

100 Deals associated with Prenoxdiazine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D08417	Prenoxdiazine Hydrochloride	R05DB18	DB13397

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cough	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis